Skip to content

Novo Is Turning to New Factories to Boost Supply of Obesity Drug

  • Wegovy seen as major growth driver despite early shortages
  • Manufacturing issues, demand have limited drug’s availability
Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen

Photographer: Christopher Goodney/Bloomberg

Two more factories will begin producing Novo Nordisk A/S’s obesity medication Wegovy next year after manufacturing issues and high demand left the drug in short supply, Chief Executive Officer Lars Fruergaard Jørgensen said in an interview Wednesday. 

Wegovy, which was approved about a year ago after helping patients lose about 15% of their body weight in research trials, is seen as a key new avenue of growth for the Danish company best known for its diabetes medications.